Compare American Airlines Group Inc (AAL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Novo Nordisk A/S — how do they compare? American Airlines Group Inc trades at $15.05 (market cap $10.55B), while Novo Nordisk A/S trades at $46.29 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 19.7× American Airlines Group Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | NVO | |
|---|---|---|
Market Cap | $10.55B | $207.85B |
Sector | Industrials | Health |
52-Week High | $18.15 | $63.98 |
52-Week Low | $10.18 | $35.29 |
Enterprise Value | $38.51B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $15.06, up 0.37% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported mixed Q2 2026 results with revenue growth but faces margin pressure from fuel costs. Analyst consensus is a Buy with a $19.63 price target, though high debt and volatile profitability remain concerns.
AAL offers potential upside from its discounted valuation and premium revenue recovery, but investors face risks from fuel price volatility, high leverage, and competitive pressures. The stock's outlook hinges on sustained travel demand and cost management amid economic uncertainty.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
